233
Participants
Start Date
September 30, 2015
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
FMX-103 1.5%
The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
FMX-103 3%
The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
Vehicle foam (0%)
The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
Berlin
Berlin
Berlin
Berlin
Mahlow
Buxtehude
Kiel
Düsseldorf
Bochum
Dülmen
Osnabrück
Mainz
Selters
Darmstadt
Stuttgart
Stuttgart
Friedrichshafen
Ulm
Blaubeuren Abbey
Schweinfurt
Vyne Therapeutics Inc.
INDUSTRY